Nektar Therapeutics’s recently made public that its Officer ROBIN HOWARD W acquired Company’s shares for reported $47338.0 on Dec 17 ’24. In the deal valued at $1.01 per share,46,995 shares were bought.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Zalevsky Jonathan sold 7,785 shares, generating $7,863 in total proceeds. Upon selling the shares at $1.01, the Chief R&D Officer now owns 243,019 shares.
Before that, Wilson Mark Andrew sold 6,407 shares. Nektar Therapeutics shares valued at $6,471 were divested by the Chief Legal Officer at a price of $1.01 per share. As a result of the transaction, Wilson Mark Andrew now holds 218,856 shares, worth roughly $0.22 million.
H.C. Wainwright initiated its Nektar Therapeutics [NKTR] rating to a Buy in a research note published on December 10, 2024; the price target was $6.50. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in early November with a ‘”an Overweight”‘ rating. Rodman & Renshaw started covering the stock on June 28, 2024. It rated NKTR as “a Buy”.
Price Performance Review of NKTR
On Tuesday, Nektar Therapeutics [NASDAQ:NKTR] saw its stock jump 2.00% to $1.02. Nektar Therapeutics shares have risen nearly 80.53% since the year began. Nevertheless, the stocks have risen 117.72% over the past one year. While a 52-week high of $1.93 was reached on 05/13/24, a 52-week low of $0.46 was recorded on 01/18/24. SMA at 50 days reached $1.2068, while 200 days put it at $1.2634.
Levels Of Support And Resistance For NKTR Stock
The 24-hour chart illustrates a support level at 1.0007, which if violated will result in even more drops to 0.9813. On the upside, there is a resistance level at 1.0347. A further resistance level may holdings at 1.0493. The Relative Strength Index (RSI) on the 14-day chart is 40.24, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0371, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 79.43%. Stochastics %K at 16.39% indicates the stock is a buying.
How much short interest is there in Nektar Therapeutics?
A steep rise in short interest was recorded in Nektar Therapeutics stocks on 2024-11-29, dropping by -0.79 million shares to a total of 4.44 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 5.23 million shares. There was a decline of -17.7%, which implies that there is a negative sentiment for the stock.
